Valuation: CS Diagnostics Corp.

Market Cap 1.82M 1.64M 1.51M 1.37M 2.56M 174M 2.59M 18.1M 7.21M 90.95M 6.85M 6.7M 289M P/E 2024
232,000x
P/E 2025 1,077x
Enterprise Value 1.82M 1.63M 1.51M 1.37M 2.55M 173M 2.58M 18.03M 7.18M 90.61M 6.82M 6.68M 288M EV / Sales 2024
1,357x
EV / Sales 2025 375x
Free-Float
14.55%
Yield 2024 *
-
Yield 2025 -
1 day+1,725.00%
Current month-14.12%
1 month-14.12%
3 months-89.57%
6 months-94.71%
Current year-97.61%
1 month 0
Extreme 0.0004
0.01
Current year 0
Extreme 0.0004
0.4
1 year 0
Extreme 0.0004
0.4
3 years 0
Extreme 0.0004
5.64
5 years 0
Extreme 0.0004
8.5
10 years 0
Extreme 0.0004
28.95
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2022
Director of Finance/CFO 47 01/01/2022
Corporate Officer/Principal 45 18/07/2024
Director TitleAgeSince
Chairman 56 25/09/1996
Director/Board Member 47 01/01/2022
Director/Board Member 54 01/09/2025
Date Insider Type Main position Quantity % Market Cap. Importance
31/12/25 Other

Chief Executive Officer

49,362,500 35.9418%
31/12/25 Other

Chief Executive Officer

104,507,800 76.0941%
31/12/25 Other

Chief Executive Officer

42,560,096 30.9888%
Change 5-day change 1-year change 3-year change Capi.($)
+1,725.00%0.00%-97.87%-94.79% 1.82M
-0.45%+2.12%-18.93%+10.54% 178B
+0.86%+2.15%-19.13%+16.07% 117B
+0.88%+1.88%+1.66%+36.51% 116B
+1.15%+1.41%-43.56%+6.76% 91.03B
-0.31%-4.72%-3.36%+72.86% 61.89B
-0.32%-0.19%+10.38%+83.80% 55.85B
+0.07%+0.42%+5.94%-22.43% 53.16B
+0.30%+1.70%-11.26%+43.83% 44.35B
+0.97%+0.48%-2.19%-7.98% 33.59B
Average +172.81%+0.85%-17.83%+14.52% 75.01B
Weighted average by Cap. +0.32%+1.25%-12.33%+24.36%

Financials

2024 2025
Net sales 111K 99.51K 92K 83.32K 156K 10.56M 158K 1.1M 438K 5.53M 416K 407K 17.55M 204K 183K 169K 153K 286K 19.43M 290K 2.02M 806K 10.17M 766K 749K 32.28M
Net income 761 682.77 631.25 571.7 1.07K 72.48K 1.08K 7.55K 3.01K 37.93K 2.86K 2.8K 120K 71.22K 63.9K 59.08K 53.5K 99.96K 6.78M 101K 706K 281K 3.55M 267K 262K 11.27M
Net Debt -501 -449.5 -415.58 -376.38 -703.17 -47.72K -711.67 -4.97K -1.98K -24.97K -1.88K -1.84K -79.27K -6.81K -6.11K -5.65K -5.12K -9.56K -649K -9.68K -67.57K -26.91K -340K -25.57K -25.03K -1.08M
Projected Income Statement - Annual - CS Diagnostics Corp.
Logo CS Diagnostics Corp.
CS Diagnostics Corp is a Germany-based medical technology and distribution company. The Company is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. It is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. It includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. CSDX Stock